Sargent Investment Group LLC Has $437,000 Stake in Novavax, Inc. (NASDAQ:NVAX)

Sargent Investment Group LLC boosted its stake in Novavax, Inc. (NASDAQ:NVAX) by 24.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 50,775 shares of the biopharmaceutical company’s stock after purchasing an additional 9,940 shares during the period. Sargent Investment Group LLC’s holdings in Novavax were worth $437,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of NVAX. State Street Corp boosted its position in Novavax by 26.7% during the third quarter. State Street Corp now owns 7,687,951 shares of the biopharmaceutical company’s stock valued at $97,099,000 after acquiring an additional 1,621,772 shares during the last quarter. Shah Capital Management boosted its position in Novavax by 13.6% during the fourth quarter. Shah Capital Management now owns 11,148,846 shares of the biopharmaceutical company’s stock valued at $89,637,000 after acquiring an additional 1,333,305 shares during the last quarter. Two Sigma Advisers LP boosted its position in Novavax by 48.9% during the third quarter. Two Sigma Advisers LP now owns 1,999,400 shares of the biopharmaceutical company’s stock valued at $25,252,000 after acquiring an additional 656,900 shares during the last quarter. Bank of Montreal Can boosted its position in Novavax by 26.7% during the third quarter. Bank of Montreal Can now owns 2,454,325 shares of the biopharmaceutical company’s stock valued at $32,643,000 after acquiring an additional 517,727 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in Novavax by 9.5% during the third quarter. Geode Capital Management LLC now owns 3,502,489 shares of the biopharmaceutical company’s stock valued at $44,245,000 after acquiring an additional 304,159 shares during the last quarter. 53.04% of the stock is currently owned by institutional investors and hedge funds.

Novavax Price Performance

NVAX stock opened at $8.60 on Thursday. The stock has a market capitalization of $1.38 billion, a PE ratio of -3.81, a price-to-earnings-growth ratio of 66.26 and a beta of 2.14. The company’s 50-day moving average is $8.80 and its 200-day moving average is $10.61. Novavax, Inc. has a 1 year low of $3.60 and a 1 year high of $23.86.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($0.83) by $0.07. The business had revenue of $84.51 million during the quarter, compared to the consensus estimate of $65.80 million. During the same period in the previous year, the business posted ($1.26) EPS. Novavax’s revenue was down 54.8% compared to the same quarter last year. On average, analysts anticipate that Novavax, Inc. will post -1.31 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have commented on NVAX. Jefferies Financial Group cut their price target on shares of Novavax from $31.00 to $25.00 and set a “buy” rating on the stock in a research report on Wednesday, October 16th. HC Wainwright reaffirmed a “buy” rating and set a $19.00 price target on shares of Novavax in a research report on Tuesday, December 10th. Finally, B. Riley reissued a “buy” rating and set a $26.00 price objective (up previously from $23.00) on shares of Novavax in a research report on Thursday, October 10th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $17.83.

Insider Activity at Novavax

In other Novavax news, Director James F. Young sold 5,400 shares of the stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $8.00, for a total value of $43,200.00. Following the completion of the sale, the director now owns 51,760 shares in the company, valued at approximately $414,080. This trade represents a 9.45 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Rachel K. King sold 4,150 shares of the stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $9.02, for a total transaction of $37,433.00. Following the completion of the sale, the director now owns 14,770 shares of the company’s stock, valued at approximately $133,225.40. This trade represents a 21.93 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 14,150 shares of company stock valued at $119,641. 1.00% of the stock is owned by corporate insiders.

Novavax Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.